Navigation Links
Mount Sinai's Arvin Dar, Ph.D., receives NIH New Innovator Award for drug development
Date:11/15/2013

Arvin Dar, PhD, structural and chemical biologist in oncological sciences at the Icahn School of Medicine at Mount Sinai, is one of 41 national recipients of the prestigious National Institutes of Health (NIH) Director's New Innovator Awards for High-Risk, High Reward Research. The award will support Dar's research into Ras-dependent cancers, specifically investigating how to combat mutations in Ras, a protein implicated in at least one of every five cancers.

Even though Ras mutations have long been known as critical drivers of cancer, metastasis, and resistance to chemotherapy, drug development in this area has been dissappointing. It turns out that the structural biology underlying Ras mutations is extremely complex.

Dr. Dar, along with other researchers at the Icahn School of Medicine at Mount Sinai and the University of California San Francisco have been instrumental in advancing this research.

Dr. Dar's laboratory has been investigating new targets or strategies that show promise in interrupting the Ras pathway. The work is highly interdisciplinary, incorporating methods from synthetic organic chemistry, mass spectrometry, informatics, biochemistry, and model organism genetics. The eventual goal is to produce new classes of small molecule drugs that impede cancers.

"NIH is excited to support visionary investigators," said NIH Director Francis S. Collins, MD, PhD. This research has "the potential to transform scientific fields and accelerate the translation of scientific research into improved health."

The NIH Common Fund, in partnership with other NIH Institutes, are key backers of the NIH Director's New Innovators Fund. These programs are designed to overcome major research barriers, specifically catalyzing disease-specific research.

In accepting the award, Dr. Dar said: "It is truly an honor to be included in this year's recipients as it is a highly competitive funding mechanism. I have benefited greatly from support and mentorship of Mount Sinai faculty, including Stuart Aaronson and Ross Cagan, as well as my postdoctoral advisor, Kevan Shokat, at the University of California San Francisco. My previous work with them has led to a compound that is currently progressing towards a human clinical trial, and this new funding will allow us to explore new avenues in drug therapy."

Thirty years ago, Mount Sinai researchers played a pivotal role in first discovering Ras mutations, and their relationship to cancer biology. Stuart Aaronson, PhD, and Prem Reddy, PhD, made significant inroads in uncovering Ras mutations.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
2. Lipitor Lawsuits Continue to Mount, as Bernstein Liebhard LLP Notes Filing of New Claim Alleging an Association Between Lipitor and Diabetes
3. Mount Sinai's Novel Gene Therapy Works to Reverse Heart Failure
4. Mount Sinai Makes Innovation a Team Effort At Its Second Annual Sinainnovations Conference, November 18-19, 2013 In NYC
5. Mount Sinai Dermatology Department in NY Opens New Practice in Chinatown
6. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
7. National Association of Professional Women Announces Elizabeth C. Abel, M.S.W., Project Director, CAPP of City of Mount Vernon-Youth Bureau, as VIP Woman of the Year
8. Newcastle, Oklahoma High School Provides Football Team with Brain Sentry Impact Sensor, Helmet-Mounted Device Helps ID Players Who Need to be Evaluated for Concussion
9. Peter R. Dottino, MD to Head Division of Gynecologic Oncology at Mount Sinai
10. Mirena Lawsuits Mount, as Bernstein Liebhard LLP Notes More than 400 Mirena IUD Lawsuit Filings in State, Federal Litigations
11. Mount Sinai and the Atlantic Host Working Summit on Big Data in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: